Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs.

Varney, Veronica; Gaga, Mina; Frew, Anthony J.; Aber, V. R.; Kay, A. B.; Durham, Stephen R.

doi:10.1136/bmj.302.6771.265

Cited by 368 publications

(244 citation statements)

References 11 publications

Supporting

Mentioning

229

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the adverse reactions that were presented during the rush IT did not exceed in intensity or frequency those reported by other authors (20)(21)(22). The absence of adverse reactions during the rest of the study with continued depot IT for three pollen seasons should be emphasized.…”

Section: Discussionmentioning

confidence: 71%

A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy

Dolz

Martínez-Cócera

Bartolomé

et al. 1996

Allergy

View full text Add to dashboard Cite

A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapv Dolz I, Martinez-C6cera C, BartolomC JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy.Allergy 1996: 51: 489-500. 0 Munksgaard 1996.Thirty patients with asthma and/or monosensitized allergic rhinitis caused by grass pollen whose ages ranged from 15 to 35 years were selected. Two groups were established at random: an active group and a placebo group, and a double-blind study was done on treatment with immunotherapy for a period of 3 continuous years, with initiation doses administered according to the rush immunotherapy technique. Grass-pollen allergen extract Alutard SQ and histamine as a placebo were used. The objective parameters of efficacy evaluated were end-point cutaneous tests, conjunctival provocation, bronchial provocation, and syniptom/medication scores, as well as specific immunoglobulin determinations. The statistical evaluation of the results was significant for the differences existing between the initial and final time of the active group, and there were significant differences between the two groups for all of the parameters considered. We found no relationship between clinical improvement and the range of specific immunoglobulin E values. Regarding the safety of the treatment, systemic adverse effects were manifested only in the initial phase (rush immunotherapy). and were easily controlled by treatment. We conclude that the efficacy and safety of immunotherapy with grass pollen make it possible to consider this treatment I fundamental in these patients.

show abstract

Section: Discussionmentioning

confidence: 71%

A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy

Dolz

Martínez-Cócera

Bartolomé

et al. 1996

Allergy

View full text Add to dashboard Cite

show abstract

“…1). They comprised a total of 3160 SIT-treated participants [SCIT with natural extracts: 440 subjects in seven trials (17)(18)(19)(20)(21)(22)(23); SCIT with allergoids: 168 SIT-treated subjects in three trials (24)(25)(26); SLIT with natural extract drops: 906 SIT-treated subjects in 16 trials (27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42); SLIT with allergoid tablets: 41 SIT-treated subjects in two trials (43,44); SLIT with natural extract tablets: 1605 SIT-treated subjects in five trials (45)(46)(47)(48)(49)(50)]. The main reasons for excluding studies were lack of double-blinding/ randomization, review articles, multiple allergen extracts, outcomes unrelated to efficacy and preparations that are not commercially available.…”

Section: Resultsmentioning

confidence: 99%

Towards evidence‐based medicine in specific grass pollen immunotherapy

Calderón

Mösges

Hellmich

et al. 2010

Allergy

View full text Add to dashboard Cite

To cite this article: Calderon M, Mö sges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 2010; 65: 420-434.We performed a systematic, evidence-based medicine (EBM) review of double-blind, placebo-controlled randomized clinical trials (DBPC RCTs) of commercially available grass pollen-specific immunotherapy (SIT) modalities for the treatment of seasonal allergic rhinoconjunctivitis (SAR) in adults and children (1). This health problem affects as many as one in seven of the population in Western countries (2, 3), with grass pollen as one of the major triggers (4).Fundamental regulatory and technological changes are modifying the types of specific subcutaneous or sublingual SIT (SCIT and SLIT) product available to specialist practitioners. The European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA) have issued guidelines affecting the clinical development of SIT products (5, 6). With the exception of Gramineae grass pollen extract SLIT tablets (currently being registered across Europe as pharmaceutical specialties), SIT products are sold as either unregistered, named patient preparations or nationally registered formulations. Hence, in many European countries, the specialist physician initiating grass pollen SIT has to choose (in collaboration with the patient) between nonregistered and registered modalities. To inform that choice, we used an EBM approach to assess commercially available immunotherapy modalities.Evidence-based medicine has been defined as 'the conscientious, explicit and judicious use of current best evidence in making decisions about the care of the individual patient' (7) and 'the integration of the best available research evidence with clinical expertise and patient values ' (8 AbstractWhen initiating grass pollen immunotherapy for seasonal allergic rhinoconjunctivitis, specialist physicians in many European countries must choose between modalities of differing pharmaceutical and regulatory status. We applied an evidence-based medicine (EBM) approach to commercially available subcutaneous and sublingual Gramineae grass pollen immunotherapies (SCIT and SLIT) by evaluating study design, populations, pollen seasons, treatment doses and durations, efficacy, quality of life, safety and compliance. After searching MEDLINE, Embase and the Cochrane Library up until January 2009, we identified 33 randomized, double-blind, placebo-controlled trials (including seven paediatric trials) with a total of 440 specific immunotherapy (SIT)-treated subjects in seven trials (0 paediatric) for SCIT with natural pollen extracts, 168 in three trials (0 paediatric) for SCIT with allergoids, 906 in 16 trials (five paediatric) for natural extract SLIT drops, 41 in two trials (one paediatric) for allergoid SLIT tablets and 1605 in five trials (two paediatric) for natural extract SLIT tablets. Trial design and quality varied significantly within and between SIT modalities. The multinational, rigorous trials of natural extract SLIT ...

show abstract

“…IT'nin kısa dönem etkinliğini gösteren bilimsel araştırmalar mevcuttur. Çayır polenleriyle yapılan bir çalışmada tedavi başlandıktan hemen sonra polen sezonunda belirgin etki gözlenmiştir (7). Bu çıkarımla moleküler standart alerjenlerle yapılan kısa süreli mevsim öncesi IT'nin bir sonraki polen mevsiminde hastaların semptomlarını azaltabileceği düşünülmüştür.…”

Section: Introductionunclassified

Evaluation of Preseasonal Immunotherapy in Patients with Seasonal Allergic Rhinitis

Tepetam¹,

Ferhan²

2014

J Chest Dis Crit Care

View full text Add to dashboard Cite

The aim of the present study was to evaluate clinical and laboratory efficacy of short term preseasonal immunotherapy by comparing immunotherapy (IT) and medical treatment administered to patients diagnosed with seasonal allergic rhinitis (AR). Patients were randomized into two groups: ie those who use preseasonal immunotherapy and drugs according to their need (IT group:12 patients ) Mevsimsel Alerjik Rinitli Hastalarda Mevsim Öncesi İmmünoterapi Etkinliğinin Değerlendirilmesi ÖZET Çalışmamızda, mevsimsel allerjik rinit (AR) tanısı koyduğumuz hastalara uygulanan mevsim öncesi immünoterapi (IT) ile medikal tedavi stratejilerini karşılaştırarak, mevsim öncesi kısa süreli immünoterapinin klinik ve laboratuvar etkinliğini değerlendirmeyi amaçladık. Hastalar mevsim öncesi IT tedavisi ile polen sezonunda ihtiyaca göre ilaç kullananlar (IT grup:12 hasta)

show abstract

Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs.

Cited by 368 publications

References 11 publications

A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy

A double‐blind, placebo‐controlled study of immunotherapy with grass‐pollen extract Alutard SQ during a 3–year period with initial rush immunotherapy

Towards evidence‐based medicine in specific grass pollen immunotherapy

Evaluation of Preseasonal Immunotherapy in Patients with Seasonal Allergic Rhinitis

Contact Info

Product

Resources

About